{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:27Z","timestamp":1790912487000,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.07.056","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:37:36Z","timestamp":1596735456000},"page":"6472-6477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus"],"prefix":"10.1016","volume":"38","author":[{"given":"Gustavo H.","family":"Dayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Forrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Frago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bouckenooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifany","family":"Machabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"DiazGranados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.07.056_b0005","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.07.056_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.056_b0015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.056_b0020","first-page":"457","article-title":"Dengue vaccine: WHO position paper \u2013 September 2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.07.056_b0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.07.056_b0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2017.11.064","article-title":"Cost-effectiveness of dengue vaccination in ten endemic countries","volume":"36","author":"Zeng","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.056_b0035","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.07.056_b0040","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2019.01956","article-title":"Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus?","volume":"10","author":"Vald\u00e9s","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.07.056_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005554","article-title":"Dissecting the human serum antibody response to secondary dengue virus infections","volume":"11","author":"Patel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.07.056_b0050","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.056_b0055","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.07.056_b0060","first-page":"5814","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2\u201311 years in Malaysia: A randomized, placebo-controlled","volume":"31","author":"Hss","year":"2013","journal-title":"Phase III study. Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.056_b0065","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9\u201316 year olds: a randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.07.056_b0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2020.07.056_b0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cid\/cix766","article-title":"Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine","volume":"66","author":"Yang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.07.056_b0080","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4161\/hv.25562","article-title":"Persistence of Th1\/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore","volume":"9","author":"Harenberg","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.07.056_b0085","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination","volume":"13","author":"Vigne","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.07.056_b0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.07.056_b0095","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4269\/ajtmh.14-0132","article-title":"Review article: Research on dengue during World War II revisited","volume":"91","author":"Snow","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.07.056_b0100","unstructured":"Coronel D, Park J, L\u00f3pez-Medina E, Capeding MR, Cadena A, Montalb\u00e1n MC, et al. Dengue vaccine: alternative vaccination schedules with reduced number of doses in healthy individuals aged 9 to 50 years in Latin America and Asia-Pacific regions (CYD65). Presented at the American Society of Tropical Medicine and Hygiene (ASTMH), 15-19 November 2019, Toronto, Ontario, Canada 2019."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:17Z","timestamp":1759402037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":20,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20309877"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}